119 related articles for article (PubMed ID: 38179997)
1. Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma.
Jia L; Cowell LG; Kapur P
Adv Anat Pathol; 2024 Mar; 31(2):96-104. PubMed ID: 38179997
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
5. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
6. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
[TBL] [Abstract][Full Text] [Related]
7. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
Singh RR; Murugan P; Patel LR; Voicu H; Yoo SY; Majewski T; Mehrotra M; Wani K; Tannir N; Karam JA; Jonasch E; Wood CG; Creighton CJ; Medeiros LJ; Broaddus RR; Tamboli P; Baggerly KA; Aldape KD; Czerniak B; Luthra R; Sircar K
Mod Pathol; 2015 Sep; 28(9):1225-35. PubMed ID: 26111976
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
10. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
11. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
13. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
17. DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC.
Wei J; Lu J; Cao Y; Yao G; Huang Y; Zhao H; Pan Y; Feng Z; Chen Z; Chen W; Luo J; Cao J
Curr Cancer Drug Targets; 2021; 21(10):849-859. PubMed ID: 34382524
[TBL] [Abstract][Full Text] [Related]
18. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
20. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
